AgroPages-WHO finds 2,4-D ‘possibly’ causes cancer in humans-Agricultural news

WHO finds 2,4-D ‘possibly’ causes cancer in humans

Related News

WHO’s International Agency for Research on Cancer (IARC) has determined that herbicide 2,4-D “possibly” causes cancer in humans, the conclusion published on Lancet Oncology yesterday.

The IARC said it reviewed the latest scientific literature and decided to classify 2,4-D as “possibly carcinogenic to humans,” a step below the more definitive “probably carcinogenic” category but two steps above the “probably not carcinogenic” category.

IARC’s findings on 2,4-D have been awaited by environmental and consumer groups that are lobbying U.S. regulators to tightly restrict the use of 2,4-D, as well as by farm groups and others that defend 2,4-D as an important agent in food production that does not need more restrictions.

In March, IARC said it had found another popular herbicide -glyphosate – was “probably carcinogenic to humans.” Glyphosate is the key ingredient in Monsanto Co’s Roundup herbicide and other products.

IARC classifications do not carry regulatory requirements but can influence regulators, lawmakers and the public. Following the glyphosate classification, some companies and government officials moved to limit glyphosate use.

Dow AgroSciences, a unit of Dow Chemical Co, has had a particular interest in IARC’s review. The company is using both glyphosate and 2,4-D in a herbicide it calls Enlist Duo that received U.S. approval last year.

Canada’s Pest Management Regulatory Agency approved the use of Enlist Duo nearly two years ago. 

Enlist Duo is designed to be used with genetically engineered, herbicide-tolerant crops developed by Dow.

Dow had no comment on the IARC classification, but the company has said 2,4-D is a safe and valuable tool for agriculture.

IARC said it decided on the “possibly” classification because there was “inadequate evidence in humans and limited evidence in experimental animals” of ties between 2,4-D and cancer. It said that epidemiological studies provided “strong evidence that 2,4-D induces oxidative stress … and moderate evidence that 2,4-D causes immunosuppression …”

However, IARC said, “epidemiological studies did not find strong or consistent increases in risk of NHL (non-Hodgkin lymphoma) or other cancers in relation to 2,4-D exposure.”

Dana Loomis, a deputy section head for IARC, said the most important studies reviewed showed mixed results, and a “sizable minority” judged the evidence as stronger than others did.

Among the research presented to IARC was an analysis funded by a Dow-backed task force that found no ties between 2,4-D and many cancers.

Some critics of 2,4-D had thought IARC would assign at least the “probably” cancer-causing classification to 2,4-D. But the Dow-backed task force said there was no reason to do so.

“Not one health and safety regulator in the world consider 2,4-D to be a human carcinogen,” the 2,4-D Research Task Force said in a statement.

Since its introduction in 1945, 2,4-D has been widely used to control weeds in agriculture, forestry, and urban and residential settings.